RTI Surgical ("RTI" or "the Company"), a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine, announced today it has successfully completed the acquisition of Collagen Solutions, a premier global supplier of engineered medical-grade collagen and xenograft tissue, as announced on October 7, 2024.
The acquisition further expands RTI's uniquely comprehensive portfolio of allograft and xenograft biomaterials at scale, building on the Company's acquisition of Cook Biotech earlier in the year. The combination brings specialized capabilities in bovine and porcine collagen materials and provides increased access to high-growth therapeutic areas such as cardiac, sports medicine and orthopedics, and plastic and reconstructive surgery. Together, the companies bring a combined 50 years of experience in developing products to help millions of patients in regenerative medicine.
Collagen Solutions is headquartered in Eden Prairie, Minnesota, with additional strategically located sites in the U.K. and New Zealand.